Evidence map›Paper›PMID 40524234›Full record

ArticleOrphanet journal of rare diseases2025

Characterizing pain in patients with Fabry disease: findings from a web-based cross-sectional survey in the US.

Eric Wallace, Dawn Laney, Ibrahim Warsi, Connie Baldwin, Jack Johnson, Joseph Kupferman, Pronabesh DasMahapatra, Nicole Lyn

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric WallaceDivision of Nephrology, Department of Medicine, University of Alabama, Birmingham, AL, USA.
Dawn LaneyDepartment of Human Genetics, School of Medicine, Emory University, Atlanta, GA, USA.
Ibrahim Warsi *Sanofi, Cambridge, MA, USA.
Connie BaldwinFabry Support & Information Group, Concordia, MO, USA.
Jack JohnsonFabry Support & Information Group, Concordia, MO, USA.
Joseph Kupferman *Sanofi, Cambridge, MA, USA.
Pronabesh DasMahapatraSanofi, Cambridge, MA, USA.
Nicole LynSanofi, Cambridge, MA, USA. Nicole.lyn@sanofi.com.ORCID http://orcid.org/0000-0001-9707-2446

Funding

Sanofi Not applicable
6 · The paper itself

Abstract

backgroundFabry disease (FD) is a rare, progressive disorder caused by pathogenic variants of the GLA gene resulting in the accumulation of toxic metabolites. Pain is a hallmark of FD, and patients often present with heterogeneous pain profiles. This cross-sectional, web-based survey was conducted to characterize pain and pain crises in patients with FD in the United States and explore the effects of sex, disease phenotypes, and treatment on pain.

resultsA total of 66 participants (mean ± standard deviation [SD] age: 44.0 ± 12.7 years; females: 59.1%) completed the survey. Participants reported experiencing pain in upper (34.8%) and lower (43.9%) extremities several times a day and abdominal pain (31.8%) a few times a week. Overall, participants reported the nature of their pain as triggered (upper extremities: 47.0%; abdomen: 51.5%) or sudden (lower extremities: 57.6%). Female participants reported experiencing pain in upper (46.2%) and lower (48.7%) extremities several times a day and described it as sudden or triggered (48.7%) in upper extremities and sudden (61.5%) in lower extremities. Pain crises were reported in the lower extremities (80.0%), followed by the upper extremities (66.7%) and the abdomen (51.1%), and were often characterized as burning, tingling, or stabbing. A higher proportion of female participants (84.6%) than that of male participants (73.7%) reported pain crises in lower extremities. The duration of pain crises varied from 30 min to several days for different subgroups depending on sex and FD phenotypes. Most participants (81.0%) reported symptom improvement after 12 months of FD-specific treatment. Participants reported improvement in neuropathic symptoms (burning in hands, 45.9%), with an overall mean (± SD) satisfaction score of 7.2 (± 1.7) with agalsidase beta as the most recent medication.

conclusionsPain was largely reported to be triggered across all subgroups. Consistent pain profiles were noted in participants across sex and FD phenotypes. Female participants reported pain burden similar to that of male participants, and pain crisis experience was heterogeneous across the subgroups. Most participants reported improvement in symptoms after FD-specific treatment and a high treatment satisfaction score with agalsidase beta.

Indexed as

Fabry DiseasePainAdultCross-Sectional StudiesFemaleHumansInternetMaleMiddle AgedSurveys and QuestionnairesUnited StatesAbdominal painFabry diseaseNeuropathic painPainPain crisesPatient-reported

Identifiers

PMID40524234
PMCPMC12172334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.